Recurrent Ovarian Carcinoma

Showing 1 - 25 of 86

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Fallopian Tube Carcinosarcoma, Primary Peritoneal Carcinosarcoma, Recurrent Fallopian Tube Carcinoma Trial in Rochester (Biopsy,

Not yet recruiting
  • Fallopian Tube Carcinosarcoma
  • +14 more
  • Biopsy
  • +6 more
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Jun 28, 2023

Recurrent Endometrial Endometrioid Adenocarcinoma, Recurrent Ovarian Carcinoma, Recurrent Ovarian Clear Cell Adenocarcinoma

Active, not recruiting
  • Recurrent Endometrial Endometrioid Adenocarcinoma
  • +4 more
  • Anchorage, Alaska
  • +584 more
Jan 28, 2023

BRCA1 Gene Mutation, BRCA2 Gene Mutation, Ovarian Serous Adenocarcinoma Trial in Buffalo, New York (biological, other, drug)

Active, not recruiting
  • BRCA1 Gene Mutation
  • +5 more
  • Durvalumab
  • +3 more
  • Buffalo, New York
  • +1 more
Jan 20, 2023

Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal

Completed
  • Platinum-Resistant Fallopian Tube Carcinoma
  • +8 more
  • Bevacizumab
  • Irinotecan Sucrosofate
  • Chicago, Illinois
    Northwestern University
Dec 21, 2022

Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma Trial in Boston, Houston

Recruiting
  • Recurrent Fallopian Tube Carcinoma
  • +2 more
  • Boston, Massachusetts
  • +1 more
Jan 12, 2023

Malignant Abdominal Tumor, Malignant Pelvic Tumor, Recurrent Colon Carcinoma Trial in Rochester (Cisplatin, Cytoreductive

Recruiting
  • Malignant Abdominal Neoplasm
  • +26 more
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Jan 5, 2023

Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal

Not yet recruiting
  • Platinum-Resistant Fallopian Tube Carcinoma
  • +5 more
  • Biopsy
  • +4 more
  • Duarte, California
    City of Hope Medical Center
Jan 3, 2023

Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma Trial

Active, not recruiting
  • Fallopian Tube Clear Cell Adenocarcinoma
  • +14 more
  • Birmingham, Alabama
  • +399 more
Dec 30, 2022

Fallopian Tube Carcinosarcoma, Fallopian Tube Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma Trial in Buffalo

Not yet recruiting
  • Fallopian Tube Carcinosarcoma
  • +10 more
  • Bevacizumab
  • +4 more
  • Buffalo, New York
    Roswell Park Cancer Institute
Dec 29, 2022

Ovarian Clear Cell Adenocarcinoma, Platinum-Sensitive Ovarian Carcinoma, Recurrent Endometrial Serous Adenocarcinoma Trial in

Not yet recruiting
  • Ovarian Clear Cell Adenocarcinoma
  • +14 more
  • Anti-CD40 Agonist Monoclonal Antibody CDX-1140
  • +4 more
  • Buffalo, New York
  • +1 more
Dec 16, 2022

Metastatic Fallopian Tube Carcinoma, Metastatic Ovarian Carcinoma, Metastatic Primary Peritoneal Carcinoma Trial in United

Active, not recruiting
  • Metastatic Fallopian Tube Carcinoma
  • +11 more
  • Phoenix, Arizona
  • +13 more
Dec 2, 2022

BRCA1 Gene Mutation, BRCA2 Gene Mutation, Locally Advanced Solid Tumor Trial in New Brunswick, New York (Laboratory Biomarker

Recruiting
  • BRCA1 Gene Mutation
  • +19 more
  • Laboratory Biomarker Analysis
  • Pembrolizumab
  • New Brunswick, New Jersey
  • +1 more
Nov 16, 2022

Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal

Active, not recruiting
  • Platinum-Resistant Fallopian Tube Carcinoma
  • +5 more
  • Tucson, Arizona
  • +16 more
Oct 19, 2022

Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma Trial in United States

Active, not recruiting
  • Recurrent Fallopian Tube Carcinoma
  • +2 more
  • Ipilimumab
  • Nivolumab
  • Auburn, California
  • +205 more
Oct 18, 2022

Ovarian Tumors, Recurrent Ovarian Carcinoma, Relapsed Ovarian Cancer Trial in Beijing (AK112 low dose, AK112 medium dose, AK112

Terminated
  • Ovarian Neoplasms
  • +3 more
  • AK112 low dose
  • +2 more
  • Beijing, Beijing, China
    Chinese Academy of Medical Sciences and Peking Union Medical Col
Oct 8, 2022

Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Tumor, Fallopian Tube Mucinous Tumor Trial in Rochester

Active, not recruiting
  • Fallopian Tube Clear Cell Adenocarcinoma
  • +22 more
  • Laboratory Biomarker Analysis
  • Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine
  • Rochester, Minnesota
    Mayo Clinic
Oct 7, 2022

Recurrent Gynecological Cancer, Metastatic Cervical Cancer, Metastatic Ovarian Cancer Trial in Boston (Durvalumab, Tremelimumab,

Terminated
  • Recurrent Gynecological Cancer
  • +10 more
  • Boston, Massachusetts
    Martin King
Oct 4, 2022

Recurrent Endometrial Carcinoma, Recurrent Ovarian Carcinoma Trial (Biopsy, Biospecimen Collection, Bone Marrow Aspiration and

Not yet recruiting
  • Recurrent Endometrial Carcinoma
  • Recurrent Ovarian Carcinoma
  • Biopsy
  • +5 more
  • (no location specified)
Sep 29, 2022

Ovarian Cancer, Oligometastatic Disease, Recurrent Ovary Cancer Trial (Stereotactic body radiotherapy)

Recruiting
  • Ovarian Neoplasms
  • +2 more
  • Stereotactic body radiotherapy
  • Campobasso, CB, Italy
  • +7 more
Sep 23, 2022

COL6A3 Positive, HLA-A*0201 Positive Cells Present, PRAME Positive Trial in Houston (biological, drug, procedure)

Active, not recruiting
  • COL6A3 Positive
  • +3 more
  • Aldesleukin
  • +4 more
  • Houston, Texas
    M D Anderson Cancer Center
Sep 22, 2022

BRCA1 Gene Mutation, BRCA2 Gene Mutation, Folate Receptor Alpha Positive Trial in Columbus (other, biological, drug)

Active, not recruiting
  • BRCA1 Gene Mutation
  • +9 more
  • Laboratory Biomarker Analysis
  • +3 more
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Sep 16, 2022

Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma Trial in

Recruiting
  • Fallopian Tube Carcinosarcoma
  • +28 more
  • Pegylated Liposomal Doxorubicin Hydrochloride
  • Peposertib
  • Aurora, Colorado
  • +7 more
Sep 2, 2022

Metastatic Malignant Solid Tumor, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma Trial in United States

Active, not recruiting
  • Metastatic Malignant Solid Neoplasm
  • +4 more
  • Laboratory Biomarker Analysis
  • +4 more
  • Phoenix, Arizona
  • +14 more
Sep 1, 2022

Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation, Endometrial Adenocarcinoma Trial in Houston (Copanlisib,

Recruiting
  • Deleterious BRCA1 Gene Mutation
  • +10 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 23, 2022

Breast Carcinoma, Fallopian Tube Carcinoma, Ovarian Carcinoma Trial in Houston (Computed Tomography, Fludeoxyglucose F-18,

Recruiting
  • Breast Carcinoma
  • +7 more
  • Computed Tomography
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 24, 2022